|
|
Vaccine Detail
|
Transgenic Lymphocyte Immunization Vaccine |
| Vaccine Information |
- Vaccine Name: Transgenic Lymphocyte Immunization Vaccine
- Target Pathogen: Cancer
- Target Disease: Cancer
- Type: whole cell cancer vaccine
- Status: Clinical trial
- Host Species for Licensed Use: None
- Antigen: telomerase (NCIT_C38720; NCT00061035)
- Immunization Route: Other
- Description: Patient's lymphocytes are rendered transgenic for a gene coding for selected portion of telomerase an enzyme expressed in the vast majority of cancer cells. Transgenic cells are then returned to the patient to produce an immune response targeted at cancer cells expressing telomerase. (NCT00061035) The transgenic cells serve as antigen- presenting cells (APCs) with the dual function of antigen synthesis and presentation. Vaccination produces an immune response targeting cancer cells expressing telomerase. (NCIT_C38720; Zanetti, 2003)
|
| Host Response |
|
|
| References |
NCIT_C38720: Transgenic Lymphocyte Immunization Vaccine [https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C38720]
NCT00061035: Evaluation of Transgenic Lymphocyte Immunization Vaccine in Subjects With Prostate Adenocarcinoma [https://clinicaltrials.gov/study/NCT00061035]
Zanetti, 2003: Zanetti M. Protocol #0207-545: a phase I/II, escalating dose, open-label evaluation of safety, feasibility, and tolerability of transgenic lymphocyte immunization (TLI) vaccine subjects with histologically proven prostate adenocarcinoma. Human gene therapy. 2003; 14(3); 301-302. [PubMed: 12653092].
|
|
